In vitro - In vivo correlations

Fabad Journal of Pharmaceutical Sciences

Volumn 28, Issue 4, 2003, Pages 215-224

  Demirtürk, Esra ^a   Öner, Levent ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

In vitro in vivo correlation

Indexed keywords

BACAMPICILLIN; PHOSPHATIDYLCHOLINE; SULFADIMIDINE; TAUROCHOLIC ACID;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CALCULATION; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DOSAGE FORM; DRUG PENETRATION; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; MEAN RESIDENCE TIME; PARAMETER; PHYSICAL CHEMISTRY; PREDICTION; REVIEW;

EID: 21744455595     PISSN: 13004182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Guidance for Industry: Extended release oral dosage forms: Development, evaluation and application of in vitro/in vivo correlations, FDA, September, 1997.
2. General Information: In vitro-in vivo correlations, American Pharmacopeia XXIV, 1927-1929, 1995.
3. Polli JE, Crison JR, Amidon GL. Novel approach to the analysis of in vitro-in vivo relationships, J. Pharm. Sci., 85, 753-759, 1996.
4. Lawrence HB, Umesh VB. Further considerations in correlating in vitro-in vivo data employing mean-time concept based on statistical moments, Drug Dev. Ind. Pharm., 14(15-17), 2143-2150, 1988.
5. Dey M, Enever R, Marino M, Michelucci J, Smith D, Warner R, Weierstall R. Sustained release etodolac bioavailability and dose proportionality: correlation between in vivo and in vitro performance, Int. J. Pharm., 49, 121-128, 1989.
6. Hwang SS, Bayne W, Theeuwes F. In vivo evaluation of controlled release products, J. Pharm. Sci., 82(11), 1145-1150, 1993.
7. Katori N, Okudaira K, Aoyagi N, Takeda Y, Uchiyama M. In vitro and in vivo correlation for controlled release formulation of d-chlorpheniramine maleate, J. Pharmacobio-Dyn., 14, 567-575, 1991.
8. Ertan G, Karasulu HY, Karasulu E, Ege MA, Kose T, Güneri T. A new in vitro-in vivo kinetic correlation method for nitrofurantoin matrix tablet formulations, Drug Dev. Ind. Pharm., 26(7), 737-743, 2000.
9. Kottke MK, Rhodes CT. Limitations of presently available in vitro release data for the prediction of in vivo performance, Drug Dev. Ind. Pharm., 17(9), 1157-1176, 1991.
10. Wagner J. Correlation of in vivo with in vitro data. Theoretical and practical considerations, Drug Intell. Clin. Pharm., 4, 160-165, 1970.
11. Sjövall J, Sjöqvist R, Huitfeldt B, Nyqvist H. Correlation between the bioavailability of microencapsulated bacampicillin hydrochloride in suspension and in vitro microcapsule dissolution, J. Pharm. Sci., 73, 141-147, 1984.
12. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12(3), 413-419, 1995.
13. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards, Eur. J. Pharm. Biopharm, 50, 3-12, 2000.
14. Sirisuth N, Eddington ND. In vitro-in vivo correlation definitions and regulatory guidance, Int. J. Gen. Drugs, www.locumusa.com/pdf/members/ivivc-01. pdf
15. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman B. Evaluation of various dissolution media for predicting in vivo performance of Class 1 and Class 11 drugs, Pharm. Res., 15(5), 698-705, 1998.
16. Amidon GL. Biopharmaceutics classification system: genesis and metamorphosis. Pharmaceutical Sciences World Congress. Kyoto-Japan, May 30-June 3 2004.
17. Löbenberg R, Kramer J, Shah VP, Amidon GL, Dressman JB. Dissolution testing as a prognostic tool for oral drug absorption: Dissolution behavior of glibenclamide, Pharm. Res., 17(4), 439-444, 2000.
18. Bakatselou V, Oppenheim RC, Dressman JB. Solubilization and wetting effects of bile salts on the dissolution of steroids, Pharm. Res., 8, 1461-1469, 1991.
19. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms, Pharm. Res., 15, 11-22, 1998.
20. Löbenberg R, Shah V, Dressman JB. In vitro-invivo correlation of two glibenclamide formulations, Second World Meeting of Biopharmaceutica, APV/APG1, Paris, 1998.
21. Smolen V. In vitro drug release tests: A quantitative approach to their development for correlation to in vivo availability, Hosp. Pharm., 4, 14-21, 1969.
22. Smolen V. The determination of the time course of in vivo pharmacological effects from the in vitro drug release testing, J. Pharm. Sci., 60, 878-883, 1971.
23. Smolen V. In vitro drug product bioequivalency requirements: What can they become?, Pharm. Technol., 1, 27-39, 1977.
24. Smolen V, Erb R. The predictive conversion of in vitro dissolution data into in vivo drug response versus time profiles exemplified for plasma levels of warfarin, J. Pharm. Sci., 66, 287-296, 1977.
25. Smolen V, Ball L, Scheffler M. Predicting the time course of in vivo bioavailability from in vitro dissolution tests: Control system engineering approaches, Pharm. Technol., 3, 89-97, 1979.
26. Podczeck F. Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT), Int. J. Pharm., 97, 93-100, 1993.
27. Mayer PR, Brazzell RK. Application of statistical moment theory to pharmacokinetics, J. Clin. Pharmacol., 28, 481-483, 1988.
28. Balan G, Timmins P, Greene DS, Marathe PH. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers, J. Pharm. Sci., 90, 1176-1185, 2001.
29. Brockmeier D, Von Hattingberg HM. Mean residence time, Methods Find. Exp. Clin. Pharmacol., 8, 309-312, 1980.
30. Kasuya Y, Hirayama H, Kubota N, Pang KS. Interpretation and estimates of mean residence time with statistical moment theory, Biopharm. Drug Dispos., 8, 223-234, 1987.
31. Cutler DJ. Theory of the mean absorption time, an adjunct to conventional bioavailability studies, J. Pharm. Pharmacol., 30, 476-478, 1978.
32. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time, J. Pharmacokinet. Biopharm., 8, 509-534, 1980.
33. Drewe J, Guitard P. In vitro-in vivo correlation for modified release formulations, J. Pharm. Sci., 82(2), 132-137, 1993.
34. Block LH, Banakar UV. Further considerations in correlating in vitro-in vivo data employing mean-time concept based on statistical moments, Drug Dev. Ind. Pharm., 14, 2143-2150, 1988.
35. Langenbucher F, Möller H. Correlation of in vitro drug release with in vivo response kinetics, Pharm. Ind., 45(6), 629-633, 1983.
36. Reitberg DP, Smith IL, Love SJ, Lewin HM, Schentag JJ. A rapid, universal TI-59 model-independent pharmacokinetic analysis program based on statistical moment theory, Drug Intel. Clin. Pharm., 19, 125-134, 1985.
37. Loo J, Riegelman S. New method for calculating the intrinsic absorption rate of drugs, J.Pharm. Sci., 57, 918-928, 1968.
38. Wagner JG. Pharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equation, J. Pharm. Sci., 72, 838-842, 1983.
39. Gillespie WR, Veng-Pedersen P. Gastrointestinal bioavailability: Determination of in vivo release profiles of solid oral dosage forms by deconvolution, Biopharm. Drug Dispos., 6, 351-355, 1985.
40. Chan KKH, Langenbucher F, Gibaldi M. Evaluation of in vivo drug release by numerical deconvolution using oral solution data as weighting function, J. Pharm. Sci., 76(6), 446-450, 1987.
41. Schartman RR, Carstensen JT. In vivo dissolution rates: An error analysis, Drug Dev. Ind. Pharm., 23(10), 967-972, 1997.
42. Langenbucher F, Möller H. Correlation of in vitro drug release with in vivo response kinetics, Pharm. Ind., 45(6), 623-628, 1983.
43. Cutler DJ. Numerical deconvolution by least squares: Use of prescribed input functions, J. Pharmacokin. Biopharm., 6, 227-241, 1978.
44. Langenbucher F. Numerical convolution/deconvolution as a tool for correlating in vitro with in vivo drug bioavailability, Pharm. Ind., 4, 1166-1172, 1982.
45. Vaughan D, Leach R. Simple transformation method for predicting plasma profiles from dissolution rates, J. Pharm. Sci., 65, 601-607, 1975.
46. Banakar U, Block L. Beyond bioavailability, Pharm. Technol., 7, 107-116, 1983.
47. Siewert M. Perspective of in vitro dissolution test in establishing in vivo/in vitro correlations, Eur. J. Drug Metab. Pharmacokinet., 18(1), 7-18, 1993.
48. Skelly JP, Amidon GL, Barr WH, Benet LZ, Carter JE, Robinson JR, Shah VP, Yacobi A. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms, Pharm. Res., 7(9), 975-981, 1990
49. Demirtürk E, Öner L. Yüksek Deǧişkenlik Gösteren İlaçlarin Biyoeşdeǧerliǧi, FABAD J. Pharm. Sci., 27, 165-172, 2002.
50. Taraszka MJ, Delor R. Effect of dissolution rate of sulfamethazine from tablets on absorption and excretion of sulfamethazine, J. Pharm. Sci., 58, 207-210, 1969.
51. Kent J, Mroszczak E, Roe R, Runkel R. Bioavailability and in vitro dissolution of tiopinac from solution and capsule formulations, Int. J. Pharm., 7, 245-252, 1981.
52. Ogata H, Aoyagi N, Kaniwa N, Koibuchi T, Ejima A, Tsuji S, Kawazu Y. The bioavailability of diazepam from uncoated tablets in humans-Part I: Correlation with the dissolution rates of the tablets, Int. J. Clin. Pharmacol. Toxicol., 20, 159-167, 1982.
53. Proost J, Bolhuis G, Lerk C. The effect of swelling capacity of disintegrants on the in vitro and in vivo availability of diazepam tablets, containing magnesium starate as a lubricant, Int. J. Pharm., 13, 287-295, 1983.
54. Levy G. Effect of certain tablet formulation factors on dissolution rate of the active ingredient, J. Pharm. Sci., 52, 1039-1047, 1963.
55. Barr W. The use of physical and animal models to assess bioavailability, Pharmacol., 8, 55-68, 1972.
56. Sirisuth N, Eddington ND. Systematic method for the development and validation of an IVIVC metoprolol and naproxen drug examples, Int. J. Gen. Drugs, www.locumusa.com/pdf/members/ivivc-03.pdf